. Non contrast-CT shows extensive multifocal intraparenchymal hemorrhages. No visible hemorrhage within the brainstem and cerebellum. Intracerebral hemorrhages were also outside the area of the ischemic infarction (Right-MCA territory in patient #1 and Left-MCA territory in patient #2). described after thrombolysis for myocardial infarction, but less common after treatment for acute ischemic stroke. 3, 4 In the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) I trial, 244 cases of symptomatic ICH were reported. 4 Most hemorrhages were large, lobar (77%), and intraparenchymal (82%), and occurred within the first 24 hours. Fifteen percent (36/244) were multifocal, and occurred significantly earlier than unifocal ICH after the administration of the thrombolytic agent (p=.002). The overall frequency of symptomatic intracranial hemorrhage in GUSTO-1 was 0.65%. Similar findings were observed in large trials using intravenous Alteplase for acute stroke. In the National Institute of Neurological Diseases (NINDS) trial, 6.4% of treated patients developed an ICH. The incidence of extra-ischemic intracranial hematomas (multifocal or not) occurred in 20% (4/20) of all t-PA related symptomatic ICH and in 1.3% (4/311) of all t-PA treated patients. 1 In the European Cooperative Acute Stroke Study (ECASS) I and II studies, the incidence of brain hemorrhages in regions without visible ischemic tissue changes was 23 of 620 (3.7%) and 16 of 800 (2.0%). 2, 5 In the Lyon study, the multifocal form of extra-ischemic parenchymal hematomas overall represented 0.6%, and 9% of all parenchymal hematomas. These studies provide no information on the possibility of a preexisting amyloid angiopathic in patients with multifocal hemorrhages.
General medical conditions have been associated with multiple and simultaneous intracranial bleeding including leukemia and other blood dyscrasias, increased fibrinogen degradation products (FDP), neoplasms, vasculitis, and venous sinus thrombosis. Although leukoaraiosis has been associated with an increase risk of bleeding post-thrombolysis, most of the intracranial hemorrhages are limited to the ischemic area. 6 In the absence of coagulopathies, defibrinogenemia, arteriovenous malformations and cerebral amyloid angiopathy (CAA) have been described. 7 Although hypertension appears to be a cofactor in the genesis of ICH, it is unclear as to the possible additive effect of arterial hypertension during the acute phase on angiopathy linked to gradient echo positive microbleeds and CAA. 8 Magnetic resonance imaging (especially T2-weighted gradient echo and FLAIR sequences) may provide useful information by detecting microhemorrhages or microangiopathy changes which increase the risk of intracerebral bleeding. 9 In a recent metanalysis, hypertension, diabetes and ischemic heart disease were associated with brain microbleeds. The authors also acknowledged several research limitations in the understanding of this medical condition. 10 Animal models studying the expression of matrix metalloproteinases have provide some clues on the possible underlying mechanisms to explain the multifocal intracranial bleeding. Studies on transgenic mice with CAA features (APP23) revealed a particular sensitivity to develop hemorrhages after rt-PA thrombolysis. 11, 12 
CONCLUSION
In conclusion, multifocal intracranial hemorrhage is uncommon, usually symptomatic, and occurs within the first 24 hours after the administration of thrombolytic therapy. The prognosis is usually poor. An MRI of the head including a gradient echo sequence may help determine remote hemorrhages associated with amyloid angiopathy.
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